(BUFFALO, NY) Feb. 15, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in vivo cellular data, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,246,486 with an expiry of 2037, which includes 189 days of Patent Term Adjustment (PTA). This US patent includes eleven claims, providing product protection for the intra and extra body data transfer methods.
This patent is the sixth issued patent for Efferent, with four pending in the US and many more pending internationally.
“This is yet another important addition to our patent portfolio which provides product protection for our CytoComm™ platform” said Bill Rader, CEO of Efferent Labs. “As we move into our first market, we will demonstrate our significant value to the pharma-biotech by providing faster information to researchers, allowing for less cost compared to current approaches. We’re very excited to continue pursuing our advanced approach to provide preclinical benefit.”
About Efferent Labs
Efferent Labs, with operations in Buffalo, N.Y., is engaged in the development and commercialization of their CytoComm™ implantable biosensor for use in pre-clinical animal research. Their technology will lower costs associated with animal research by >20% and provide researchers with real-time data at the cellular level. The company is currently on track to commercialize their first biosensor platform, CytoComm™, in mid-2023.
